Table 2.

Changes in inotrope, vasopressor, and iloprost dosages during periods 1 and 2.

	Pre-levosimendan	Period 1	Period 2
Epinephrinea, mg/h	1.3 ± 1.2	0.4 ± 0.4*	0.3 ± 0.4*
Norepinephrinea, mg/h	1.0 ± 0.8	0.3 ± 0.3*	0.15 ± 0.2*
Milrinonea, mg/h	1.5 ± 0.6	0.9 ± 0.7*	0.8 ± 0.9*
Iloprostb, µ/d	54 ± 10	43 ± 11*	32 ± 20*
IABP	42 (40)	42 (40)	42 (40)

Data are presented as mean ± standard deviation or n (%).

Period 1: within 24 hours from the initiation of treatment with levosimendan; Period 2: >24 to <48 hours from the initiation of treatment with levosimendan; IABP, intra-aortic balloon pump.

^aMaximum doses used during the respective period.

^bCumulative doses used during the respective period.

*p < 0.05 in comparison with pre-levosimendan values.